BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

At its investor day event on Wednesday, BioMarin (BMRN) unveiled its long-term plans for growth, including potential drug approvals and revenue guidance over the next 10 years. Management also updated the company's organizational structure, splitting its existing business into three separate segments — skeletal conditions, enzyme therapies and Roctavian. Enzyme therapies include Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim. BMRN Boasts $5B+ Revenue Opportunity From Voxzogo Management expects Voxzog ...